Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data: Femara helped reduce risk of breast-cancer recurrence an additional 19%
June 16th, 2005
Femara (letrozole tablets) treatment of postmenopausal women with early breast cancer prolonged disease-free survival by reducing the risk of recurrence an additional 19% (p=0.003) over that offered by tamoxifen when used as initial treatment after surgery, according to data from the Breast International Group (BIG) 1-98 study. Even more importantly, use of Femara resulted in greater disease-free survival in two subgroups of women who are at particularly increased risk of recurrence - those whose cancer had already spread to the lymph nodes at the time of diagnosis (node positive) and those who had received chemotherapy. The risk reductions in these subgroups were 29%...
Source: Women's Health Weekly (2005-06-16)
|
